NEUROPATHIX, INC.
company.status.inactiveCIK 1615999fmd_15J4EH83QX7R80E2R0BHEMZAFFManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Mar 31, 2022, 28 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | – | – | – | – |
| Net interest income | – | – | (0) | (0) | – | – | – |
| Gross profit | 0 | 0 | 0 | – | – | – | – |
| Realized investment gains (losses) | – | – | 0 | 4 | 0 | – | – |
| Provision for credit losses | – | – | 0 | 0 | – | – | – |
| Net interest income after provision | – | – | (0) | (0) | – | – | – |
| Research and development | – | – | 0 | 0 | 1 | 1 | 0 |
| Selling, general and administrative | 0 | 0 | 0 | – | – | – | – |
| Total operating expenses | 0 | 0 | 1 | 1 | 2 | 4 | 3 |
| Operating income | 0 | (0) | (1) | (1) | (2) | (4) | (3) |
| Non-interest expense | – | – | – | 0 | 0 | 0 | 0 |
| Interest expense | – | – | – | 0 | 0 | 1 | 0 |
| Other non-operating income (expense) | – | – | (0) | 3 | (1) | (0) | (1) |
| Income before taxes | 0 | (0) | (1) | 2 | (3) | (5) | (4) |
| Income tax expense | – | 0 | 0 | 1 | 0 | 0 | 0 |
| Net income from continuing operations | – | (0) | (2) | 1 | (3) | (5) | (4) |
| Net income | 0 | (0) | (2) | 1 | (3) | (5) | (4) |
| Net income to common shareholders | – | – | – | 1 | (3) | (5) | – |